SIL204 shows dose-dependent inhibition in KRAS G12D lung cancer cells in preclinical study

Silexion Therapeutics Corp

Preclinical study demonstrates significant dose-dependent inhibition of human lung cancer cells with KRAS G12D mutation.
Company plans to release results of new study on previously untested KRAS mutation shortly; if positive, could support pan-KRAS potential.
SIL204's lipid-conjugated delivery system validated; overcoming a key barrier for siRNA in solid tumors.
Company continues to prepare for Phase 2/3 trial initiation in Q2 2026 for KRAS-driven solid tumors.
Builds on prior efficacy in pancreatic and colorectal cancer models; KRAS mutations occur in ~30% of lung cancers.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.